Reply to thread

Message

Did you look over the thread I dropped in 2020?

Have you read the full paper from 2021 which includes any limitations in the study?

TT troughs (IM vs sub-q) were nothing to brag about.

Even then keep in mind this is not true trough (7 days post-injection) as blood was drawn 5-6 days after the last injection.

*Men were either treated with IM-TC alone, SCTE-AI alone or started with IM-TC and crossed over to SCTE-AI with at least 6 weeks of washout between the 2 treatment modalities. Dosing for IM-TC and SCTE-AI was 100 mg weekly.

*Serum values of TT (280 to 1,100 ng/dL), E2 (10 to 50 pg/mL), HCT (38.8% to 50.0%) and PSA (<2.5 ng/mL) were drawn prior to initiation of TRT and at 12-week followup. Baseline laboratory blood draws were specified to occur in the morning prior to 10:00 a.m. and 5-6 days after their last injection to observe trough TT values.

*After an average follow-up of 14.2 weeks after initiating TRT, both cohorts had significant increases in trough TT compared to their baseline levels (IM-TC:313.6 ng/dL to 536.4 ng/dL, p <0.001; SCTE-AI: 246.6ng/dL to 552.8 ng/dL, p <0.001)

*Post-therapy, the SCTE-AI cohort had significantly lower, HCT and E2, while TT and PSA levels were not significantly different between the treatment arms.

post #26 (full paper)
[URL unfurl="true"]https://www.excelmale.com/forum/threads/intramuscular-versus-subcutaneous-testosterone-injections-effect-on-tt-hematocrit-e2-and-psa.22223/[/URL]

Limitations

This is the first study of the novel SCTE-AI indirect comparison to another TRT modality for the treatment of hypogonadism in men. Limitations to this study include its retrospective nature preventing randomization of patients. We also acknowledge the limitations associated with the portion of participants who had been treated with both TRT modalities, of whom all had received IM-TC prior to switching to SCTE-AI. This was performed due to constraints with our relatively small sample size. A washout period was utilized prior to SCTE-AI initiation, though a more robust study in the future would compare independent patient pools that receive only 1 TRT modality. While testosterone enanthate and testosterone cypionate are both short-acting testosterone esters, our analysis of the SCTE-AI and IM-TC compares 2 different formulations of injectable testosterone. Furthermore, our databases lacked depth in clinical information, such as body mass index, or relevant medication use, such as aromatase inhibitors, which is rarely used in tandem with TRT in our practices. We acknowledge these factors may act as unknown confounders. Lastly, as the SCTE-AI is a newer device, future studies will benefit from larger sample sizes and longer follow-ups as the SCTE-AI becomes more widely used.

<blockquote data-quote="madman" data-source="post: 272483" data-attributes="member: 13851">Did you look over the thread I dropped in 2020?Have you read the full paper from 2021 which includes any limitations in the study?TT troughs (IM vs sub-q) were nothing to brag about.Even then keep in mind this is not true trough (7 days post-injection) as blood was drawn 5-6 days after the last injection.*Men were either treated with IM-TC alone, SCTE-AI alone or started with IM-TC and crossed over to SCTE-AI with at least 6 weeks of washout between the 2 treatment modalities. Dosing for IM-TC and SCTE-AI was 100 mg weekly.*Serum values of TT (280 to 1,100 ng/dL), E2 (10 to 50 pg/mL), HCT (38.8% to 50.0%) and PSA (&lt;2.5 ng/mL) were drawn prior to initiation of TRT and at 12-week followup. Baseline laboratory blood draws were specified to occur in the morning prior to 10:00 a.m. and 5-6 days after their last injection to observe trough TT values.*After an average follow-up of 14.2 weeks after initiating TRT, both cohorts had significant increases in trough TT compared to their baseline levels (IM-TC:313.6 ng/dL to 536.4 ng/dL, p &lt;0.001; SCTE-AI: 246.6ng/dL to 552.8 ng/dL, p &lt;0.001)*Post-therapy, the SCTE-AI cohort had significantly lower, HCT and E2, while TT and PSA levels were not significantly different between the treatment arms.post #26 (full paper)[URL unfurl=&quot;true&quot;]https://www.excelmale.com/forum/threads/intramuscular-versus-subcutaneous-testosterone-injections-effect-on-tt-hematocrit-e2-and-psa.22223/[/URL]LimitationsThis is the first study of the novel SCTE-AI indirect comparison to another TRT modality for the treatment of hypogonadism in men. Limitations to this study include its retrospective nature preventing randomization of patients. We also acknowledge the limitations associated with the portion of participants who had been treated with both TRT modalities, of whom all had received IM-TC prior to switching to SCTE-AI. This was performed due to constraints with our relatively small sample size. A washout period was utilized prior to SCTE-AI initiation, though a more robust study in the future would compare independent patient pools that receive only 1 TRT modality. While testosterone enanthate and testosterone cypionate are both short-acting testosterone esters, our analysis of the SCTE-AI and IM-TC compares 2 different formulations of injectable testosterone. Furthermore, our databases lacked depth in clinical information, such as body mass index, or relevant medication use, such as aromatase inhibitors, which is rarely used in tandem with TRT in our practices. We acknowledge these factors may act as unknown confounders. Lastly, as the SCTE-AI is a newer device, future studies will benefit from larger sample sizes and longer follow-ups as the SCTE-AI becomes more widely used.</blockquote>

[QUOTE="madman, post: 272483, member: 13851"] Did you look over the thread I dropped in 2020? Have you read the full paper from 2021 which includes any limitations in the study? TT troughs (IM vs sub-q) were nothing to brag about. Even then keep in mind this is not true trough (7 days post-injection) as blood was drawn 5-6 days after the last injection. [B][I]*Men were either treated with IM-TC alone, SCTE-AI alone or [U]started with IM-TC and crossed over to SCTE-AI with at least 6 weeks of washout between the 2 treatment modalities[/U]. [U]Dosing for IM-TC and SCTE-AI was 100 mg weekly[/U].[/I][/B] [I][B]*Serum values of TT (280 to 1,100 ng/dL), E2 (10 to 50 pg/mL), HCT (38.8% to 50.0%) and PSA (<2.5 ng/mL) were drawn prior to initiation of TRT and at 12-week followup. [/B][/I][B][I][B][U]B[/U][/B][U][B]aseline laboratory blood [/B]draws were specified to occur in the morning prior to 10:00 a.m. and 5-6 days after their last injection to observe trough TT values[/U]. *After an average follow-up of 14.2 weeks after initiating TRT, [U]both cohorts had significant increases in trough TT compared to their baseline levels[/U] (IM-TC:313.6 ng/dL to 536.4 ng/dL, p <0.001; SCTE-AI: 246.6ng/dL to 552.8 ng/dL, p <0.001)[/I][/B] [I][B]*Post-therapy, the SCTE-AI cohort had significantly lower, HCT and E2, [/B][/I][B][I][B][U]while [/U][/B][U]TT[/U] and PSA [U]levels were not significantly different between the treatment arms[/U].[/I][/B] [I][B]post #26 (full paper)[/B][/I] [URL unfurl="true"]https://www.excelmale.com/forum/threads/intramuscular-versus-subcutaneous-testosterone-injections-effect-on-tt-hematocrit-e2-and-psa.22223/[/URL] [B]Limitations[/B] [I]This is the first study of the novel SCTE-AI indirect comparison to another TRT modality for the treatment of hypogonadism in men. [B]Limitations to this study include its retrospective nature preventing randomization of patients. [U]We also acknowledge the limitations associated with the portion of participants who had been treated with both TRT modalities, of whom all had received IM-TC prior to switching to SCTE-AI[/U]. This was performed due to constraints with our relatively small sample size. [U]A washout period was utilized prior to SCTE-AI initiation, though a more robust study in the future would compare independent patient pools that receive only 1 TRT modality[/U]. While testosterone enanthate and testosterone cypionate are both short-acting testosterone esters, [U]our analysis of the SCTE-AI and IM-TC compares 2 different formulations of injectable testosterone[/U].[/B] [B][U]Furthermore, our databases lacked depth in clinical information, such as body mass index, or relevant medication use, such as aromatase inhibitors, which is rarely used in tandem with TRT in our practices[/U]. [U]We acknowledge these factors may act as unknown confounders[/U]. Lastly, as the SCTE-AI is a newer device, future studies will benefit from larger sample sizes and longer follow-ups as the SCTE-AI becomes more widely used.[/B][/I] [/QUOTE]